{"id":715,"date":"2026-05-22T22:01:45","date_gmt":"2026-05-23T02:01:45","guid":{"rendered":"https:\/\/www.durhampeptides.ca\/post\/cjc-1295-ipamorelin-blend-explained"},"modified":"2026-06-22T14:17:38","modified_gmt":"2026-06-22T18:17:38","slug":"cjc-1295-ipamorelin-blend-explained","status":"publish","type":"post","link":"https:\/\/www.durhampeptides.ca\/fr\/post\/cjc-1295-ipamorelin-blend-explained","title":{"rendered":"CJC-1295 + Ipamorelin Blend Explained: The Dual-Pathway GH Research Peptide"},"content":{"rendered":"<figure><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-205\" src=\"https:\/\/www.durhampeptides.ca\/wp-content\/uploads\/2026\/10\/CJC-1295_DP.png\" alt=\"CJC-1295 Ipamorelin blend dual pathway growth hormone research peptide Durham Peptides Canada\" width=\"1024\" height=\"1536\" srcset=\"https:\/\/www.durhampeptides.ca\/wp-content\/uploads\/2026\/10\/CJC-1295_DP.png 1024w, https:\/\/www.durhampeptides.ca\/wp-content\/uploads\/2026\/10\/CJC-1295_DP-200x300.webp 200w, https:\/\/www.durhampeptides.ca\/wp-content\/uploads\/2026\/10\/CJC-1295_DP-683x1024.webp 683w, https:\/\/www.durhampeptides.ca\/wp-content\/uploads\/2026\/10\/CJC-1295_DP-768x1152.webp 768w, https:\/\/www.durhampeptides.ca\/wp-content\/uploads\/2026\/10\/CJC-1295_DP-800x1200.webp 800w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n<p>CJC-1295 Ipamorelin blend dual pathway growth hormone research peptide Durham Peptides Canada<\/p>\n<p><\/p>\n<p>The CJC-1295 + Ipamorelin blend is the single most-studied growth-hormone secretagogue combination in peptide research, and the logic behind it is elegant: rather than pushing one lever of growth-hormone release harder, it pulls two complementary levers at once. By pairing a GHRH-analog (CJC-1295) with a selective ghrelin-receptor agonist (Ipamorelin), the blend engages the two distinct upstream pathways that converge on growth-hormone-releasing somatotroph cells of the pituitary \u2014 a combination that published preclinical data suggests produces greater GH elevation than either compound alone.<\/p>\n<p><\/p>\n<p>This article explains what each component does, why the combination is studied together, and what researchers examine when they use the blend. For Canadian researchers, Durham Peptides supplies the <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/product-page\/cjc-1295-ipamorelin-blend-10mg\/\" target=\"_blank\">CJC-1295 (No DAC) + Ipamorelin Blend 10mg<\/a><\/u>. Nothing here is medical, dosing, or therapeutic guidance.<\/p>\n<p><\/p>\n<p><strong>The Two Pathways of Growth-Hormone Release<\/strong><\/p>\n<p><\/p>\n<p>Growth-hormone secretion from the pituitary is governed by several upstream signals. Two of them are the targets of this blend:<\/p>\n<ol><li><strong>The GHRH pathway.<\/strong> Growth-hormone-releasing hormone (GHRH) binds the GHRH receptor on pituitary somatotrophs and stimulates the synthesis and release of growth hormone. This is the primary \"go\" signal for GH production.<\/li><li><strong>The ghrelin \/ GHS pathway.<\/strong> Ghrelin (and synthetic ghrelin mimetics) binds the growth-hormone secretagogue receptor (GHS-R1a) and amplifies the <em>amplitude<\/em> of GH pulses, working through a mechanism distinct from GHRH.<\/li><\/ol>\n<p><\/p>\n<p>Because these two pathways act through different receptors and different intracellular signals, activating both simultaneously is studied for producing a synergistic \u2014 not merely additive \u2014 effect on GH release. This dual-pathway synergy is the central rationale for the blend, and for the broader practice of combining a GHRH analog with a ghrelin mimetic, which is discussed in depth in <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/post\/growth-hormone-secretagogues-explained\/\" target=\"_blank\">Growth Hormone Secretagogues Explained<\/a><\/u>.<\/p>\n<p><\/p>\n<p><strong>Component 1: CJC-1295 (No DAC) \u2014 the GHRH Analog<\/strong><\/p>\n<p><\/p>\n<p><u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/product-page\/cjc-1295-no-dac-10mg\/\" target=\"_blank\">CJC-1295 (No DAC)<\/a><\/u> is a 30-amino-acid analog of GHRH, also known as Modified GRF (1-29). Its key identity data:<\/p>\n<ul><li><strong>CAS number:<\/strong> 446036-97-1<\/li><li><strong>Molecular weight:<\/strong> 3367.9 g\/mol<\/li><li><strong>Class:<\/strong> GHRH receptor agonist<\/li><\/ul>\n<p><\/p>\n<p>The \"No DAC\" designation is important. The original CJC-1295 molecule included a Drug Affinity Complex (DAC) that bound to serum albumin, extending its half-life to several days. The <strong>No DAC<\/strong> version omits that complex, giving it a short half-life (on the order of minutes). That short half-life is a deliberate research feature: it allows the compound to stimulate a GH pulse and then clear, preserving the body's natural <em>pulsatile<\/em> pattern of GH secretion rather than producing a continuous elevation. Researchers studying pulsatile GH dynamics specifically favor the No-DAC form for this reason.<\/p>\n<p><\/p>\n<p><strong>Component 2: Ipamorelin \u2014 the Selective Ghrelin-Receptor Agonist<\/strong><\/p>\n<p><\/p>\n<p><u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/product-page\/ipamorelin-10mg\/\" target=\"_blank\">Ipamorelin<\/a><\/u> is a pentapeptide (five amino acids) that selectively activates the GHS-R1a (ghrelin) receptor. Its key identity data:<\/p>\n<ul><li><strong>CAS number:<\/strong> 170851-70-4<\/li><li><strong>Molecular weight:<\/strong> 711.85 g\/mol<\/li><li><strong>Class:<\/strong> Selective growth-hormone secretagogue (GHS) receptor agonist<\/li><\/ul>\n<p><\/p>\n<p>Ipamorelin's defining research characteristic is its <em>selectivity<\/em>. Earlier-generation growth-hormone-releasing peptides (such as GHRP-6 and GHRP-2) also stimulate GH but tend to raise cortisol and prolactin as well. Ipamorelin was characterized in the literature as the first GHS that stimulates GH with minimal effect on cortisol and prolactin \u2014 making it a cleaner research tool for isolating GH-release effects. Like CJC-1295 No DAC, it has a short half-life that preserves pulsatile secretion.<\/p>\n<p><\/p>\n<p><strong>Why the Blend Combines Them<\/strong><\/p>\n<p><\/p>\n<p>Durham Peptides' <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/product-page\/cjc-1295-ipamorelin-blend-10mg\/\" target=\"_blank\">CJC-1295 (No DAC) + Ipamorelin Blend<\/a><\/u> contains:<\/p>\n<ul><li><strong>5mg CJC-1295 (No DAC)<\/strong> \u2014 the GHRH-pathway component<\/li><li><strong>5mg Ipamorelin<\/strong> \u2014 the ghrelin-pathway component<\/li><li><strong>10mg total<\/strong>, in a 1:1 ratio<\/li><\/ul>\n<p><\/p>\n<p>The combination is studied because the two compounds engage GH release through complementary, non-overlapping mechanisms:<\/p>\n<ul><li>CJC-1295 increases the <em>synthesis and release<\/em> of GH through the GHRH receptor.<\/li><li>Ipamorelin increases the <em>amplitude<\/em> of the GH pulse through the GHS receptor.<\/li><\/ul>\n<p><\/p>\n<p>When both pathways are activated concurrently, published preclinical data suggests a greater GH response than either pathway produces alone \u2014 the basis of the \"GHRH + GHS synergy\" that has been documented across the secretagogue literature. The 1:1, both-short-half-life design preserves the natural pulsatile profile while engaging both axes. For the head-to-head breakdown of the two components, see <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/post\/cjc-1295-vs-ipamorelin\/\" target=\"_blank\">CJC-1295 vs Ipamorelin: Why Researchers Combine Them<\/a><\/u>.<\/p>\n<p><\/p>\n<p><strong>What Researchers Examine<\/strong><\/p>\n<p><\/p>\n<p>In research protocols using the blend, common areas of investigation include:<\/p>\n<ul><li>Synergistic GH release: GHRH analog + GHS agonist combination versus monotherapy<\/li><li>Pulsatile GH secretion patterns in pituitary cell models<\/li><li>Downstream IGF-1 effects under combined GHRH\/GHS activation<\/li><li>Comparative analysis versus single-compound administration<\/li><li>Optimal component ratios for dual-pathway GH research protocols<\/li><\/ul>\n<p><\/p>\n<p><strong>The Convenience Factor<\/strong><\/p>\n<p><\/p>\n<p>Beyond the pharmacology, the blend has a practical research advantage: it eliminates the need to reconstitute, calculate, and store two separate vials for a combination protocol. A single co-reconstituted vial produces consistent per-unit amounts of both components. For the reconstitution math, the <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/peptide-calculator\/\" target=\"_blank\">peptide calculator<\/a><\/u> handles the volume calculations, and <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/post\/how-to-reconstitute-peptides\/\" target=\"_blank\">How to Reconstitute Peptides<\/a><\/u> covers the physical protocol. Both components reconstitute in <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/product-page\/bacteriostatic-water-10ml\/\" target=\"_blank\">eau bact\u00e9riostatique<\/a><\/u> and store under the same conditions.<\/p>\n<p><\/p>\n<p><strong>Quality Standards<\/strong><\/p>\n<p><\/p>\n<p>Durham Peptides' blend is verified to \u226599% purity <em>per component<\/em> by HPLC, with mass-spectrometry identity confirmation for both peptides through Janoshik Analytical, each batch carrying an independently verifiable COA key. Per-component verification matters for a blend \u2014 you want confirmation that both peptides are present, identified, and pure, not just an aggregate number. For how to read those documents, see <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/post\/how-to-read-janoshik-coa\/\" target=\"_blank\">How to Read a Janoshik COA<\/a><\/u> and the <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/lab-results\/\" target=\"_blank\">R\u00e9sultats de laboratoire<\/a><\/u> .<\/p>\n<p><\/p>\n<p><strong>Questions fr\u00e9quentes<\/strong><\/p>\n<p><\/p>\n<p><strong>What is the CJC-1295 + Ipamorelin blend?<\/strong> A dual-pathway growth-hormone research peptide combining CJC-1295 (No DAC), a GHRH-receptor agonist, with Ipamorelin, a selective ghrelin-receptor agonist, in a 1:1 (5mg + 5mg) ratio.<\/p>\n<p><\/p>\n<p><strong>Why are CJC-1295 and Ipamorelin used together?<\/strong> They activate GH release through two complementary pathways \u2014 GHRH and ghrelin\/GHS \u2014 and published preclinical data suggests the combination produces greater GH elevation than either compound alone.<\/p>\n<p><\/p>\n<p><strong>What does \"No DAC\" mean in CJC-1295?<\/strong> \"No DAC\" means the molecule omits the Drug Affinity Complex, giving it a short half-life that preserves the natural pulsatile pattern of GH secretion, unlike the long-acting DAC version.<\/p>\n<p><\/p>\n<p><strong>Is Ipamorelin selective?<\/strong> Yes. Ipamorelin is characterized as a selective GHS agonist that stimulates GH with minimal effect on cortisol and prolactin, distinguishing it from earlier GHRPs.<\/p>\n<p><\/p>\n<p><strong>Can I buy CJC-1295 and Ipamorelin separately?<\/strong> Yes. Durham Peptides stocks <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/product-page\/cjc-1295-no-dac-10mg\/\" target=\"_blank\">CJC-1295 (No DAC)<\/a><\/u> et <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/product-page\/ipamorelin-10mg\/\" target=\"_blank\">Ipamorelin<\/a><\/u>individually, as well as the <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/product-page\/cjc-1295-ipamorelin-blend-10mg\/\" target=\"_blank\">combined blend<\/a><\/u>.<\/p>\n<p><strong>How is the blend stored?<\/strong> 2\u20138\u00b0C short-term, -20\u00b0C long-term, protected from light and moisture; reconstitute in bacteriostatic water.<\/p>\n<p><\/p>\n<p><strong>Final Thoughts<\/strong><\/p>\n<p><\/p>\n<p>The CJC-1295 + Ipamorelin blend endures as a research staple because its design is genuinely rational: two short-acting compounds, two distinct pathways, one pulsatile-preserving combination studied for synergistic GH release. For Canadian researchers, Durham Peptides supplies the <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/product-page\/cjc-1295-ipamorelin-blend-10mg\/\" target=\"_blank\">CJC-1295 (No DAC) + Ipamorelin Blend 10mg<\/a><\/u> at C$95.00, Janoshik-verified per component.<\/p>\n<p><\/p>\n<p>For the component comparison, see <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/post\/cjc-1295-vs-ipamorelin\/\" target=\"_blank\">CJC-1295 vs Ipamorelin<\/a><\/u>; for the category context, see <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/post\/growth-hormone-secretagogues-explained\/\" target=\"_blank\">Growth Hormone Secretagogues Explained<\/a><\/u>; and for the buying decision, see <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/post\/buy-cjc-1295-ipamorelin-canada\/\" target=\"_blank\">Buy CJC-1295 + Ipamorelin in Canada<\/a><\/u>.<\/p>\n<p><\/p>\n<p><strong>Selected Research References<\/strong><\/p>\n<p><\/p>\n<ol><li>Teichman SL, Neale A, Lawrence B, et al. Prolonged Stimulation of Growth Hormone and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GHRH. <em>Journal of Clinical Endocrinology &amp; Metabolism<\/em>. 2006;91(3):799-805. <u><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/16352683\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/16352683\/<\/a><\/u><\/li><li>Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the First Selective Growth Hormone Secretagogue. <em>European Journal of Endocrinology<\/em>. 1998;139(5):552-561. <u><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/9849822\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/9849822\/<\/a><\/u><\/li><li>Bowers CY, Momany FA, Reynolds GA, Hong A. On the In Vitro and In Vivo Activity of a New Synthetic Hexapeptide That Acts on the Pituitary to Specifically Release Growth Hormone. <em>Endocrinology<\/em>. 1984. <u><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/1349865\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/1349865\/<\/a><\/u><\/li><\/ol>\n<p><\/p>\n<p><em>All products sold by Durham Peptides are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease.<\/em><\/p>","protected":false},"excerpt":{"rendered":"CJC-1295 Ipamorelin blend dual pathway growth hormone research peptide Durham Peptides Canada The CJC-1295 + Ipamorelin blend is the single most-studied growth-hormone secretagogue combination in peptide research, and the logic behind it is elegant: rather than pushing one lever of growth-hormone release harder, it pulls two complementary levers at once. By pairing a GHRH-analog (CJC-1295) with a selective ghrelin-receptor agonist (Ipamorelin), the blend engages the two distinct upstream...","protected":false},"author":1,"featured_media":205,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[55],"tags":[],"class_list":["post-715","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-research-science"],"_links":{"self":[{"href":"https:\/\/www.durhampeptides.ca\/fr\/wp-json\/wp\/v2\/posts\/715","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.durhampeptides.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.durhampeptides.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.durhampeptides.ca\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.durhampeptides.ca\/fr\/wp-json\/wp\/v2\/comments?post=715"}],"version-history":[{"count":1,"href":"https:\/\/www.durhampeptides.ca\/fr\/wp-json\/wp\/v2\/posts\/715\/revisions"}],"predecessor-version":[{"id":1056,"href":"https:\/\/www.durhampeptides.ca\/fr\/wp-json\/wp\/v2\/posts\/715\/revisions\/1056"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.durhampeptides.ca\/fr\/wp-json\/wp\/v2\/media\/205"}],"wp:attachment":[{"href":"https:\/\/www.durhampeptides.ca\/fr\/wp-json\/wp\/v2\/media?parent=715"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.durhampeptides.ca\/fr\/wp-json\/wp\/v2\/categories?post=715"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.durhampeptides.ca\/fr\/wp-json\/wp\/v2\/tags?post=715"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}